Huntington's disease

The properties of benzodiazepine receptors in samples of six areas of cerebral cortex from patients and controls matched with respect to age, sex, and postmortem delay have been studied by in vitro radioligand binding techniques. A statistically significant 30 to 40% increase in the number of benzodiazepine and allosterically linked GABA-A receptors is observed in the midfrontal cortex (A9/A10), but in no other cortical region examined. The degree of enhancement of [3H]diazepam binding by a given dose of GABA or pentobarbital is significantly reduced in Huntington's disease midfrontal cortex. As in the case of receptor number changes, other cortical regions examined show less prominent changes in regulation of benzodiazepine binding by GABA or pentobarbital. Direct identification of the benzodiazepine binding subunit by photoaffinity labeling with [3H]flunitrazepam reveals a single species of apparent molecular weight 51 kD in patients and controls, suggesting that gross changes in structure of the benzodiazepine binding subunit do not account for the observed alterations in benzodiazepine receptor regulation.

[1]  R. Aster,et al.  New approaches to an old problem , 1988 .

[2]  G. E. Alexander,et al.  Parallel organization of functionally segregated circuits linking basal ganglia and cortex. , 1986, Annual review of neuroscience.

[3]  S. Folstein,et al.  Neurotransmitter receptor alterations in Huntington's disease: Autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes , 1985, Annals of neurology.

[4]  S. Snyder,et al.  Localization of type I benzodiazepine receptors to postsynaptic densities in bovine brain , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[5]  G A McPherson,et al.  A practical computer-based approach to the analysis of radioligand binding experiments. , 1983, Computer programs in biomedicine.

[6]  R. Olsen.  Drug interactions at the GABA receptor-ionophore complex. , 1982, Annual review of pharmacology and toxicology.

[7]  F. Goodwin,et al.  Cholecystokinin receptors are decreased in basal ganglia and cerebral cortex of Huntington's disease , 1981, Brain Research.

[8]  C. Gardner,et al.  Endogenous GABA determines the characteristics of [3H]GABA-binding. , 1981, European journal of pharmacology.

[9]  A. Snowman,et al.  Barbiturate receptor sites are coupled to benzodiazepine receptors. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Rossor,et al.  Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease , 1980, Brain Research.

[11]  E. Spokes,et al.  Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. , 1980, Brain : a journal of neurology.

[12]  E. Bird,et al.  Alterations in the benzodiazepine receptor of Huntington's diseased human brain , 1979, Brain Research.

[13]  J. Tallman,et al.  GABAergic modulation of benzodiazepine binding site sensitivity , 1978, Nature.

[14]  K. Beaumont,et al.  Muscimol binding in rat brain: Association with synaptic GABA receptors , 1978, Brain Research.

[15]  L. Iversen,et al.  Human brain substance P: distribution in controls and Huntington's chorea , 1978, Journal of neurochemistry.

[16]  J. Fields,et al.  Alterations in dopaminergic receptors in Huntington's disease. , 1977, Life sciences.

[17]  L. Iversen,et al.  Huntington's chorea: Selective depletion of activity of angiotensin converting enzyme in the corpus striatum , 1977, Annals of neurology.

[18]  L. Stern,et al.  Huntington's disease: regional alteration in muscarinic cholinergic receptor binding in human brain. , 1976, Life sciences.

[19]  L. Iversen,et al.  Reduced glutamic-acid-decarboxylase activity of post-mortem brain in Huntington's chorea. , 1973, Lancet.

[20]  T. Perry,et al.  Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. , 1973, The New England journal of medicine.